DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA463404
Title:
The Role of hCDC4 as a Tumor Suppressor Gene in Genomic Instability Underlying Prostate Cancer
Descriptive Note:
Annual summary rept. 1 Nov 2004-31 Oct 2006
Corporate Author:
SIDNEY KIMMEL CANCER CENTER SAN DIEGO CA
Report Date:
2006-11-01
Pagination or Media Count:
10.0
Abstract:
This study investigates the role of a newly identified gene called hCDC4 in prostate cancer. The hCDC4FBXW7 gene encodes a protein that functions in a cellular process called proteolysis, or protein degradation. hCdc4 degrades a protein called cyclin E1, which is a central component of the cell division machinery. Cyclin E1 is involved in initiating DNA replication in cells. However, in many types of human tumors cyclin E1 protein level is aberrant and this phenotype has been shown in vitro and in vivo to be oncogenic. Very little is known regarding cyclin E1hCdc4 in prostate tumors. We are exploring whether hCDC4FBXW7 functions as a tumor suppressor gene in prostate cancer. We have completed a genetic screen of prostate tumors and found an hCDC4FBXW7 gene mutation. We have shown that this mutant hCdc4 cannot bind cyclin E1 substrate in vivo and mislocalizes in cells. We are currently exploring the effects of hCDC4FBXW7 knockdown in prostate cancer progression and identifying substrates of dysregulation of cyclin E1 kinase activity due to hCDC4FBXW7 inactivation using protein array technology.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE